Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRCT-101SR + NRCT-202XR in pediatric ADHD
NCT06673368Phase 2Terminated
- Sponsor
- Neurocentria Inc.
- Start
- Feb 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NRCT-101SR in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Neurocentria Inc. Primary endpoints: Clinical Global Impression-Severity at 6 weeks and Side Effects Rating Scale at 6 weeks. Started Feb 2025; status: terminated.
02
Drugs
NRCT-101SR
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06673368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673368.